MARKET

YMTX

YMTX

Yumanity Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.29
+0.19
+1.35%
Opening 12:53 05/17 EDT
OPEN
14.29
PREV CLOSE
14.10
HIGH
15.23
LOW
13.95
VOLUME
52.52K
TURNOVER
--
52 WEEK HIGH
36.80
52 WEEK LOW
13.82
MARKET CAP
145.67M
P/E (TTM)
-0.6623
1D
5D
1M
3M
1Y
5Y
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 2d ago
Yumanity Therapeutics EPS misses by $0.04, beats on revenue
Yumanity Therapeutics (YMTX): Q1 GAAP EPS of -$0.85 misses by $0.04.Revenue of $3.53M beats by $3.03M.Press Release
Seekingalpha · 4d ago
Yumanity Therapeutics Q1 EPS $(0.85) Up From $(3.47) YoY, Sales $3.53M
Yumanity Therapeutics (NASDAQ:YMTX) reported quarterly losses of $(0.85) per share. This is a 75.5 percent increase over losses of $(3.47) per share from the same period last year. The company reported $3.53 million in
Benzinga · 4d ago
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
Demonstrated lead program YMTX-7739 inhibits novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson’s disease Initiated dosing in Phase 1b portion of multi-dose trial of YMTX-7739 in patients wi...
GlobeNewswire · 4d ago
-- Earnings Flash (YMTX) YUMANITY THERAPEUTICS Posts Q1 Revenue $3.5M
MT Newswires · 4d ago
Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference
BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced th...
GlobeNewswire · 5d ago
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 05/07 11:40
Yumanity Therapeutics to Host Virtual R&D Day on Monday, May 17, 2021
Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that the Company will host a virtual R&D Day on Monday, May 17, 2021 at ...
GlobeNewswire · 05/04 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of YMTX. Analyze the recent business situations of Yumanity Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average YMTX stock price target is 77.00 with a high estimate of 160.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 82
Institutional Holdings: 23.13M
% Owned: 226.93%
Shares Outstanding: 10.19M
TypeInstitutionsShares
Increased
5
25.97K
New
10
2.62M
Decreased
12
13.47K
Sold Out
20
111.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+0.78%
Key Executives
Chairman/Executive Board
N. Anthony Coles
President/Chief Executive Officer/Director
Richard Peters
Chief Financial Officer
Paulash Mohsen
Executive Vice President/Vice President - Research & Development
Ajay Verma
Chief Accounting Officer
Marie Epstein
Chief Scientific Officer
Benito Munoz
Other
Geoffrey Gilmartin
Director
Patricia Allen
Director
Richard Heyman
Director
Cecil Pickett
Director
Lynne Zydowsky
Independent Director
David Arkowitz
Independent Director
Kimberlee Drapkin
Independent Director
Jeffery Kelly
No Data
About YMTX
Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The Company’s pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

Webull offers kinds of Yumanity Therapeutics Inc stock information, including NASDAQ:YMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading YMTX stock methods without spending real money on the virtual paper trading platform.